Gregory Barone, DO
Endocrinology, Diabetes & Metabolism · Cherry Hill, NJNPI 1104016187
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $386,968 of the $432,941 with a category attached, or 89.4%. 21 manufacturers reported payments, led by Lilly USA, LLC at 59.9% of the total. Among endocrinology, diabetes & metabolism clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 937 payments — averaging $462.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$259K
- Novo Nordisk$135K
- AstraZeneca$34K
- Medtronic$2K
- Abbott$1K
- Boehringer Ingelheim$213
- plus $1K from 15 others
What the payments were for
- Consulting fees$1,6250%
- Speaking & faculty fees$386,96889%
- Travel & lodging$29,1367%
- Food & beverage$15,1924%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 604 | $259,140 |
| Novo Nordisk | 152 | $135,144 |
| AstraZeneca | 62 | $34,045 |
| Medtronic(2 entities) | 12 | $2,049 |
| Abbott | 77 | $1,144 |
| Boehringer Ingelheim | 3 | $213 |
| Tandem Diabetes Care, Inc. | 5 | $143 |
| Valeritas, Inc. | 1 | $143 |
| Bayer | 2 | $132 |
| Johnson & Johnson | 2 | $115 |
| Zealand Pharma US, Inc. | 1 | $115 |
| Mannkind Corporation | 1 | $100 |
| Companion Medical, Inc. | 1 | $86 |
| BD | 1 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Dexcom, Inc. | 2 | $68 |
| Cequr Corporation | 2 | $41 |
| Corcept Therapeutics | 3 | $36 |
| Insulet Corporation | 2 | $31 |
| Ascendis Pharma Endocrinology Inc | 2 | $28 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$181,469
- Ozempic$59,141
- RYBELSUS$55,957
- TRULICITY$51,251
- FARXIGA$33,065
- Tresiba$7,589
- Xultophy 100/3.6$1,880
- Minimed 670G System$1,496
- Guardian Connect$220
- MINIMED 780G$155
- V-GO$143
- FreeStyle Libre 2$129
- Kerendia$125
- V-GO DISPOSABLE INSULIN DELIVERY$115
- INVOKANA$110
- JARDIANCE$105
- AFREZZA$100
How this compares
$432,941 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 448 | $729,129 |
| TrulicityDulaglutide | 225 | $367,663 |
| JardianceEmpagliflozin | 189 | $250,010 |
| FarxigaDapagliflozin Propanediol | 172 | $220,582 |
| MounjaroTirzepatide | 110 | $166,041 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $153,093 |
| Tresiba Flextouch U-100Insulin Degludec | 148 | $113,346 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $108,799 |
| JanuviaSitagliptin Phosphate | 60 | $66,159 |
| Bydureon BciseExenatide Microspheres | 40 | $61,799 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $60,022 |
| RybelsusSemaglutide | 40 | $59,458 |
| Humalog Kwikpen U-100Insulin Lispro | 128 | $51,218 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $47,344 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 40 | $47,338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $135,144 | $797,274509 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $259,140 | $554,939387 claims |
| Boehringer IngelheimJardiance | $213 | $250,010189 claims |
| AstraZenecaFarxiga | $34,045 | $220,582172 claims |
| MerckJanuvia, Janumet Xr | $14 | $81,61572 claims |
| Johnson & JohnsonInvokana | $115 | $40,03525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
Other endocrinology, diabetes & metabolism in Cherry Hill
- Parveen VermaCherry Hill$73K
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Navtika DesaiHillsborough$408K
- Taher ModarressiPennington$402K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.